NVL1 for Diagnosing PTSD
We are developing an objective detection mechanism for PTSD. Our diagnostic takes advantage of brain imaging technology in order to visualize our PTSD biomarker in real-time. Our first patent-pending radiotracer, NVL-1, was developed in mid-2017. Since then, we have developed and synthesized a novel class of tracers. Optimization, pre-clinical validation, and additional development are underway.
Currently, PTSD is diagnosed with checklists after symptoms have manifested. The checklist method (using either the Structured Clinical Interview for DSM (SCID) – PTSD Module, or the Clinical Administered PTSD Scale (CAPS)/Life Events Checklist) is subjective. Furthermore, the reliance on self-report and self-assessment leads to both underdiagnosis and misdiagnosis.
We aim to diagnose PTSD faster and more accurately than ever before. Our tracer will provide an objective indication of PTSD in a patient, irrespective of manifestation of symptoms. No more ambiguity–we may detect and distinguish PTSD from other disorders. Swift diagnosis also means nearly immediate intervention and streamlining treatment routing, potentially saving on treatment costs getting soldiers and civilians alike healthy again. This tool can also direct to our treatment, and may be used as an enrollment tool for future treatment studies. And for the first time ever, we can put an end to the stigma by showing that PTSD is indeed a visible wound.
Our diagnostic tracer has potential applications beyond PTSD for use with other GluA1-implicated disorders, such as ALS, epilepsy, and Alzheimer’s Disease.